A disintegrin and metalloproteinase 10 (ADAM10) is a synaptic enzyme that has been previously shown to limit amyloid-β1-42 (Aβ1-42) peptide formation in Alzheimer's disease (AD). Furthermore, ADAM10 participates to spine shaping through the cleavage of adhesion molecules and its activity is under the control of synaptic plasticity events. In particular, long-term depression (LTD) promotes ADAM10 synaptic localization triggering its forward trafficking to the synapse, while long-term potentiation elicits ADAM10 internalization. Here, we show that a short-term in vitro exposure to Aβ1-42 oligomers, at a concentration capable of inducing synaptic depression and spine loss, triggers an increase in ADAM10 synaptic localization in hippocampal neuronal cultures. However, the Aβ1-42 oligomers-induced synaptic depression does not foster ADAM10 delivery to the synapse, as the physiological LTD, but impairs ADAM10 endocytosis. Moreover, Aβ1-42 oligomers-induced inhibition of ADAM10 internalization requires neuronal activity and the activation of the NMDA receptors. These data suggest that, at the synaptic level, Aβ1-42 oligomers trigger an aberrant plasticity mechanism according to which Aβ1-42 oligomers can downregulate Aβ generation through the modulation of ADAM10 synaptic availability. Moreover, the increased activity of ADAM10 towards its synaptic substrates could also affect the structural plasticity phenomena. Overall, these data shed new lights on the strict and complex relationship existing between synaptic activity and the primary mechanisms of AD pathogenesis.

Amyloid-β oligomers regulate ADAM10 synaptic localization through aberrant plasticity phenomena / E. Marcello, S. Musardo, L. Vandermeulen, S. Pelucchi, F. Gardoni, N. Santo, F. Antonucci, M. Di Luca. - In: MOLECULAR NEUROBIOLOGY. - ISSN 0893-7648. - 56:10(2019 Apr 13), pp. 7136-7143. [10.1007/s12035-019-1583-5]

Amyloid-β oligomers regulate ADAM10 synaptic localization through aberrant plasticity phenomena

E. Marcello
Primo
;
S. Musardo
Secondo
;
L. Vandermeulen;S. Pelucchi;F. Gardoni;N. Santo;F. Antonucci
Penultimo
;
M. Di Luca
Ultimo
2019

Abstract

A disintegrin and metalloproteinase 10 (ADAM10) is a synaptic enzyme that has been previously shown to limit amyloid-β1-42 (Aβ1-42) peptide formation in Alzheimer's disease (AD). Furthermore, ADAM10 participates to spine shaping through the cleavage of adhesion molecules and its activity is under the control of synaptic plasticity events. In particular, long-term depression (LTD) promotes ADAM10 synaptic localization triggering its forward trafficking to the synapse, while long-term potentiation elicits ADAM10 internalization. Here, we show that a short-term in vitro exposure to Aβ1-42 oligomers, at a concentration capable of inducing synaptic depression and spine loss, triggers an increase in ADAM10 synaptic localization in hippocampal neuronal cultures. However, the Aβ1-42 oligomers-induced synaptic depression does not foster ADAM10 delivery to the synapse, as the physiological LTD, but impairs ADAM10 endocytosis. Moreover, Aβ1-42 oligomers-induced inhibition of ADAM10 internalization requires neuronal activity and the activation of the NMDA receptors. These data suggest that, at the synaptic level, Aβ1-42 oligomers trigger an aberrant plasticity mechanism according to which Aβ1-42 oligomers can downregulate Aβ generation through the modulation of ADAM10 synaptic availability. Moreover, the increased activity of ADAM10 towards its synaptic substrates could also affect the structural plasticity phenomena. Overall, these data shed new lights on the strict and complex relationship existing between synaptic activity and the primary mechanisms of AD pathogenesis.
ADAM10; Alzheimer disease; Amyloid-β; synaptic plasticity
Settore BIO/14 - Farmacologia
H20MCITNIF15MDILU_M - Synaptic Dysfunction in Alzheimer Disease - DILUCA, MONICA MARIA GRAZIA - H20MCITNIF - Horizon 2020_Marie Skłodowska-Curie actions-Innovative Training Network (ITN)/Individual Fellowships (IF) - 2015
PRIN201517MDILU - Meccanismi di patogenesi negli stadi precoci della malattia di Alzheimer: identificazione di target armacologici e biomarkers - DILUCA, MONICA MARIA GRAZIA - PRIN2015 - PRIN bando 2015 - 2017
PON18MRIVA_01 - Medicina personalizzata per strategie innovative in malattie neuro-psichiatriche e vascolari (PerMedNet) - RIVA, MARCO ANDREA - PON PNR 2015-2020 - 2018
DECC18ACORS_01 - Dipartimenti di Eccellenza 2018-2022 - Dipartimento di SCIENZE FARMACOLOGICHE E BIOMOLECOLARI - CORSINI, ALBERTO - DECC - Bando Dipartimenti di Eccellenza - 2018
2014-RIC-0026 - Validating ADAM10 as therapeutic target for dementia - MARCELLO, ELENA - INTLI - Finanziamenti internazionali - 2014
2014-RIC-0024 - Development of innovative tools for Alzheimer Disease therapy - MARCELLO, ELENA - INTLI - Finanziamenti internazionali - 2014
FFABR18ACORS_01 - Fondo per il finanziamento delle attività base di ricerca - DIPARTIMENTO DI SCIENZE FARMACOLOGICHE E BIOMOLECOLARI - CORSINI, ALBERTO - FFABR - Fondo per il finanziamento delle attività base di ricerca - 2018
13-apr-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
bnYSOO-Marcello2019_Article_Amyloid-βOligomersRegulateADAM.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 2.24 MB
Formato Adobe PDF
2.24 MB Adobe PDF Visualizza/Apri
s12035-019-1583-5.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 2.24 MB
Formato Adobe PDF
2.24 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/639925
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact